DCBO vs. ENFN, OPRA, FSLY, TUYA, PDFS, BASE, VTEX, MOMO, KC, and EVBG
Should you be buying Docebo stock or one of its competitors? The main competitors of Docebo include Enfusion (ENFN), Opera (OPRA), Fastly (FSLY), Tuya (TUYA), PDF Solutions (PDFS), Couchbase (BASE), VTEX (VTEX), Hello Group (MOMO), Kingsoft Cloud (KC), and Everbridge (EVBG). These companies are all part of the "prepackaged software" industry.
Docebo (NASDAQ:DCBO) and Enfusion (NYSE:ENFN) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking.
Docebo received 43 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 66.67% of users gave Docebo an outperform vote while only 18.75% of users gave Enfusion an outperform vote.
In the previous week, Docebo had 16 more articles in the media than Enfusion. MarketBeat recorded 19 mentions for Docebo and 3 mentions for Enfusion. Enfusion's average media sentiment score of 0.45 beat Docebo's score of -0.34 indicating that Enfusion is being referred to more favorably in the news media.
Enfusion has lower revenue, but higher earnings than Docebo. Docebo is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Docebo currently has a consensus target price of $55.00, indicating a potential upside of 48.01%. Enfusion has a consensus target price of $9.33, indicating a potential downside of 2.68%. Given Docebo's stronger consensus rating and higher probable upside, equities research analysts plainly believe Docebo is more favorable than Enfusion.
53.2% of Docebo shares are owned by institutional investors. Comparatively, 81.1% of Enfusion shares are owned by institutional investors. 36.4% of Enfusion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Docebo has a net margin of 3.55% compared to Enfusion's net margin of 1.40%. Docebo's return on equity of 19.31% beat Enfusion's return on equity.
Docebo has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Summary
Docebo beats Enfusion on 12 of the 18 factors compared between the two stocks.
Get Docebo News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCBO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
